NEW YORK (GenomeWeb News) - Japan's National Cancer Research Institute is using Nonlinear Dynamics' 2D gel analysis software in research aimed at discovering and validating biomarkers for cancer diagnostics, the company said today.
The NCRI is using the company’s Progenesis SameSpots image analysis platform to develop biomarker candidates that would predict response to the cancer therapy gefitinib in lung adenocarcinoma. The project is also planning to identify markers that will predict a patient's risk of cancer recurrence, the company said.
The NCRI’s clinical proteomics group currently runs more than 1,500 2D-DIGE gels per year.
Financial terms of the agreement were not released.